University of Michigan Medical School
|
|
Hematology-Oncology |
| Ann Arbor VA Medical
Center and University of Michigan Medical School |
|
|||
|
This resource provides access to materials protected by United States and/or international copyright law. It is intended to facilitate "fair use" by those with legitamate access to these works. Learn more about copyright and fair use. |
|||
Site-Specific Resources |
NCI
Guidance  NCCN Guidelines Cancer-Matrix |
|
| Site | Treatment | Regimen | Links | Citation | Order Template | ||
| Hematology | |||||||
| Lymphoma | |||||||
| Non-Hodgkins | |
||||||
| CHOP | CHOP | Abs | Armitage JO 1984 J Clin Oncol 2:898 |
CHOP | |||
| intermediate and high grade NHL | Rituximab | Rituximab | Abs | Coiffler B 1998 Blood 92:1927 |
Rituximab | ||
| low grade/ follicular NHL |
Abs | McLaughlin P 1998 J Clin Oncol 16:2825 |
|||||
| RCHOP-Gela | RCHOP-Gela | Abs | Coiffler B 2002 New Engl J Med 346:235 |
RCHOP-Gela | |||
| ICE | ICE | Abs | Moskowitz CH 1999 J Clin Oncol 17:3776 |
ICE | |||
| RICE | RICE | Abs | Kewalramani T 2004 Blood 103:3684 |
RICE | |||
| CEPP | CEPP | Abs | Chao NJ 1990 Blood 76:1293 |
CEPP | |||
| CVP - oral cyclophosphamide | CVP | Cit | Bagley CM Jr 1972 Ann Intern Med 76:227 |
CVP-po | |||
| Abs | Hoppe RT 1981 Blood 58:592 |
||||||
| CVP - i.v. cyclophosphamide | CVP-iv | Abs | Marcus R 2005 Blood 105:1417 |
CVP-iv | |||
| RCVP | RCVP | Abs | Marcus R 2005 Blood 105:1417 |
R-CVP | |||
| ChlVPP | ChlVPP | Abs | Selby P 1990 Br J Cancer 62:279 |
ChlVPP | |||
| Abs | Int'l ChlVPP Trtmt Grp 1995 Ann Oncol 6:167 |
||||||
| Abs | Hancock BW 2001 Br J Cancer 84:1291 |
||||||
| Hodgkin's Disease | |
||||||
| ABVD | ABVD | Abs | Bonadonna G 1975 Cancer 36:252 |
ABVD | |||
| MOPP | MOPP | Cmt | Canellos 2002 N Engl J Med 346:1417 |
MOPP | |||
| Abs | Canellos 1992 N Engl J Med 327:1478 |
MOPP | |||||
| Leukemia | |||||||
| AML, APL | |
||||||
| Induction | Daunorubicin 3 + 7 w/Cytarabine (Ara C) 100 mg/M2 |
Daun3and7-100 |
Abs | Wiernik PH 1992 Blood 79:313 |
Daun3and7-100 |
||
| Daunorubicin 3 + 7 w/Cytarabine (Ara C) 200 mg/M2 |
Daun3and7-200 | Abs | Mayer RJ 1994 N Engl J Med 331:896 |
Daun3and7-200 | |||
| Idarubicin 3 + 7 - w/Cytarabine (Ara C) 100 mg/M2 |
Ida3and7-100 | Abs | Wiernik PH 1992 Blood 79:313 |
Ida3and7-100 | |||
| Relapsed | High-Dose Ara-C (cytarabine) - 12-dose age > 50 y |
HiDAC-12-2000 | Abs | Karanes C 1999 Leuk Res 23:787 |
HiDAC-12-2000 | ||
| High-Dose Ara-C (cytarabine) - 12-dose age < 51 y |
HiDAC-12-3000 | Abs | Karanes C 1999 Leuk Res 23:787 |
HiDAC-12-3000 | |||
| High-Dose Ara-C (cytarabine) - intensive consolidation |
HiDAC-consolidation | Abs | Mayer RJ 1994 N Engl J Med 331:896 |
HiDAC-consolidation | |||
| Abs | Karanes C 1999 Leuk Res 23:787 |
||||||
| MEC - mitoxantrone, etoposide, int.-dose cytarbine |
MEC | Abs | Amadori S 1991 J Clin Oncol 9:1210 |
MEC | |||
| Abs | Greenberg PL 2004 J Clin Oncol 22:1078 |
||||||
| APL | ATRA, daunorubicin, cytarabine 45/60/200 |
ATRA3+7-200 | Abs | Fenaux P 1999 Blood 94:1192 |
ATRA3+7-200 | ||
| ALL | Larson | ||||||
| Intergroup Phase II | |||||||
| Other | |||||||
| CLL | |
||||||
| FCR | FCR | Abs | Keating MJ 2005 J Clin Oncol 23:4079 |
FCR | |||
| Abs | Bergsagel DE 1979 New Engl J Med 301:743 |
||||||
| Fludarabine | Fludarabine | Abs | Rai KR 2000 New Engl J Med 343:1750 |
Fludarabine | |||
| Chlorambucil and Prednisone |
ChlorambPred-7day | 11023504 | Robak T 2000 Blood 96:2723 |
ChlorambPred-7day | |||
| Hairy Cell | |
||||||
| Cladribine (2-CdA) single agent |
Cladribine | Abs | Chadha P 2005 Blood 106:241 |
Cladribine | |||
| ITP | Vincristine - single agent | Vincristine | Abs | Sikorska A 2004 Clin Lab Haematol 26:407 |
Vincristine | ||
| Myeloma | |
||||||
| Melphalan and Prednisone | MelphalanPred | Abs | Abramson N 1982 Ca Treat Rep 66:1273 |
MelphalanPred | |||
| Abs | Oken MM 1997 Cancer 79:1561 |
||||||
| VAD | VAD | 6546971 | Barlogie B 1984 N Engl J Med 310:1353 |
VAD | |||
| Site | Treatment | Regimen | Links | Citation | Order Template | ||
| Oncology | |||||||
| Head and Neck | |
||||||
| larynx | |
||||||
| organ preservation | chemo/RT | VA larynx | Abs | VALCSG 91 NEJM 324:1685 |
|||
| Forastiere | Abs | Forastiere 03 NEJM 349:2091 |
forastiere-larynx | ||||
| Brizel | Abs | Brizel
98 NEJM 338:1798 |
brizel | ||||
| Denis | Abs | Denis 04 JCO 22:69 |
|||||
| hypopharynx | |
||||||
| chemo/RT | Lefebvre/EORTC | Abs | Lefebvre
96 JNCI 88:890 |
||||
| Brizel | Abs | Brizel
98 NEJM 338:1798 |
brizel | ||||
| nasopharynx | |
||||||
| chemo+RT | Al-Sarraf/Int0099 | Abs | Al-Sarraf 98 JCO 16:1310 |
al-sarraf | |||
| multiple | |||||||
| 5-FU+cisplat+RT | Brizel | Abs | Brizel
98 NEJM 338:1798 |
brizel | |||
| chemo+RT | Adelstein 2000 | Abs | Adelstein
00 |
||||
| chemo+RT | Adelstein 2002 | Abs | Adelstein 02 JCO 20:1405 |
||||
| chemo+RT | Adelstein 2003 | Abs | cisrad | ||||
| capecitabine+cisplat+RT | Kim 2005 | Abs | Kim 05 Br J Cancer 93:1117 |
CapCis | |||
| post-op | chemo+RT | Cooper 2004 | Abs | cisrad | |||
| recurrent | FU+cisplat | Jacobs | Abs | Jacobs
92 J Clin Oncol 10:257 |
|||
| FU+carbo | |||||||
| Taxol+cisplat | Adamo | Abs | Adamo 04 Oral Onc 40:525 |
||||
| Cetuximab vx Cisplatin | Magrini | Magrini 15 J Clin Oncol 33 |
|||||
| Systemic Therapy Review | Pancari | Pancari 15 Surg Clin N A 24:437 |
|||||
| Lung | |
||||||
| Small Cell | |
||||||
| chemo+RT (bid vs qd) | Turrisi 1999 | Abs | Turrissi | cisplatvp1 | |||
| cisplat+vp dose resp. | Ihde 1994 | Abs | Ihde
94 J Clin Oncol 12:2022 |
cis-vp | |||
| carbo+vp | Skarlos 2001 | Abs | carbo-vp | ||||
| Irino+cis vs cis+VP16 | Noda | Abs | Noda 02 NEJM 346:85 |
||||
| NSCLC | |
||||||
| chemo/RT review | Ruff | Ruff 03 Onc SE 1:18 |
|||||
| NSCLC, resected | Adjuvant carbo+tax vs cis+nav | Chang 2014 | Lung Cancer 84:51 | ||||
| Adeno, pre-op | Neoadjuvant: carbo+pem+bev | Ou 2016 | Cancer, Mar1:740 | ||||
| NSC, III | chemo/RT | ||||||
| carbo+taxol induction->CRT | Socinski/UNC | Abs | Socinski
00 Cancer 89:534 |
unc-chemo-rt | |||
| Rosenman/UNC | Abs | Rosenman 02 IJROBP 54:348 |
unc-chemo-rt | ||||
| chemo+RT | Sause | Sauce
00 Chest 117:358 |
|||||
| metaanalysis | Pritchard 1996 | Abs | Pritchard
96 Ann Int Med 125:723 |
||||
| carbo+taxol CRT (no induction) | Vokes 2007 | Abs | Vokes 07 JCO 25:1698 |
||||
| Carbo+taxol vs cis+etop, w/RT | Santana-Davila 2015 | JCO 33:567 | |||||
| NSC, IV | General Approach | Ruff | Ruff 03 Onc SE 1:18 |
||||
| carbo+taxol (7/175) | Kosmidis 1997 | Abs | Kosmidis 00 Ann Onc 11:799 |
carbo-tax7_175 beta | |||
| carbo+taxol (6/200) | Kosmidis 2002 | Abs | Kosmidis 02 JCO 20:3578 |
carbo-tax6_200 | |||
| gem+cisplat | Scagliotti 2002 | Abs | Scagliotti
02 JCO 20:4285 OS Curve |
||||
| gem+cisplat | Abratt 1997 | Abs | gen-cis-abratt | ||||
| gemzar+taxol(1000/200) | Kosmidis 2002 | Abs | Kosmidis 02 JCO 20:3578 |
gem-tax | |||
| platinum regimens RCT | Scagliotti 2002 | Abs | Scagliotti
02 JCO 20:4285 OS Curve |
||||
| docetaxel+carboplatin | Millward 2003 | Abs | doce-carbo | ||||
| docetaxel+gemcitabine | Niho 2003 | Abs | doce-gem | ||||
| Agent selction by histology | Einhorn 08 | JCO 26:3485 | |||||
| ROS1 -> crizotinib | Box 2013 | Lung Cancer 81:142 | |||||
| 6 vs fewer cycles | Rossi 2014 | Lancet Onc 15:1254 | |||||
| Non-squamous | CarboPemBev vs CarboTaxBev | Patel 2013 | |||||
| Evaluation | PET-CT | Bradley 2004 | Bradley 04 IJROBP 59:78 |
||||
| PET editorial | Paulino 2004 | Paulino 2004 IJROBP 59:4 |
|||||
| PET in Oncology | Czernin 2002 | Czernin 2002 Acta Med Austriaca 29:162 |
|||||
| Esophagus | |
||||||
| EUS Staging | Rice 2003 | Rice 2003 JTCV Surg 125:1091 |
|||||
| TFC->FC+XRT->Surgery | Swisher 2003 | Swisher 2003 IJROBP 57:120 |
|||||
| Pre-Op CisplatFU+RT | Kleinberg 2003 | Kleinberg 2003 IJROBP 56:328 |
|||||
| Pre-Op ChemoRT of Adeno Ca | Walsh 1996 | Walsh 96 NEJM 335:462 |
|||||
| Walsh f/u correspondence | (various) 1997 | various 97 NEJM 336:374 |
|||||
| Meta-analysis | Urschel 2003 |
Urschel 2003 AJ Surg 185:538 |
|||||
| Meta-analysis (excludes MAGIC) | Gebski 2007 | Abs | Gebski 07 Lancet Onc 8:226 |
||||
| ChemoRT review | Kleinberg 2007 | Abs | Kleinberg 07 JCO 25:4110 |
||||
| Pre-Op Chemo, ChemoRT review | Gebski07 | Abs | Gebski 07 Lancet Onc 8:226 |
||||
| Celiac Axis Node Issues | Frizzell 2003 | Frizzell 2003 AJCO 26:215 |
|||||
| Squamous | INT 122 ChemoRT toxicity | Minsky 1996 | Abs | Minsky 96 JCO 14:149 |
|||
| Pre-Op Chemo (no RT) | Kelsen 1998 | Abs | Kelsen 98 NEJM 339:1979 |
||||
| INT113 Pre-Op Chemo (no RT) | Kelsen 2007 | Abs | Kelsen 07 JCO 25:3719 |
||||
| MRC Cis + 5FU pre-Op (no RT) | MRC-OCWP 2002 | Abs | MRCOCWP 02 Lancet 359:1727 |
||||
| Adeno | MAGIC ECF pre & post op (no RT) | Cunningham 2006 | Abs | Cunningham 06 NEJM |
|||
| Squamous | ChemoRT->Surg v ChemoRT alone | Bedenne 2007 | Abs | Bedenne 07 JCO 25:1160 |
|||
| Induction | CisTax->CisTaxRT->Surg MSKCC 3-Step |
Bains 2002 | Abs | Bains 02 J Thor CV Surg 124:270 |
|||
| Induction - Adeno | CisFU->ChemoRT->Surg IrinoDoceFU->ChemoRT->Surg |
Malaisrie 2006 | Abs | Malaisrie 06 Cancer 107:967 |
|||
| Primary/Definitive CRT | Primary ChemoRT | Minsky 2006 | Abs | HTML | Minsky 06 Oncology 20:497 |
||
| INT0123 ChemoRT (50.4 v 64.8 Gy) | Minsky 2002 | Abs | Minsky 02 JCO 20:1167 |
50.4: = efficacy, less tox | |||
| unresectable | RTOG 85-01 ChemoRT v RT | Cooper
1999 |
Abs | Cooper
99 JAMA 281:1623 correspondence |
Herskovic | ||
| rec/metastatic | |||||||
| Stomach/GE Junction | |
||||||
| adjuvant | MacDonald | Abs | MacDonald
01 NEJM 345:725 |
gastric-adj | |||
| metastatic | Taxol+5FU | Murad | |||||
| Pancreas | |
||||||
| adjuvant | RT + 5FU PVI | Mehta | Abs | fu-sens-rt | |||
| Whittington | Abs | fu-sens-rt | |||||
| Osti | Abs | ||||||
| rec/metastatic | gemcitabine | Burris | Abs | ||||
| gemcitabine+capecitabine | Hess | Abs | Hess 03 JCO 21:66 |
gem-cap | |||
| gemcitabine+cisplat | Phillip | Abs | Philip 01 Cancer 92:569 |
gem-cis | |||
| Liver, Bile Ducts | Liver | |
|||||
| Bile Duct | |||||||
| confined | sensFU+RT | Whittington | Abs | ||||
| transplantation | Yoo | Yoo
03 JCO 21:4329 |
|||||
| Colon | |
||||||
| adjuvant | FL+Oxaliplatin | Andre | Andre 04 NIJM 350:2343 |
||||
| 5-FU+Levamisole, 12 month | Moertel 1995 | Abs | |||||
| 5-FU+Leuc, qDx5, 6 month | O'Connell 1997 | Abs | fuleuc-dx5-adj | ||||
| 5-FU+ Leuc, weekly | Wolmark 1993 |
Abs | fuleuc-wk-adj | ||||
| Leucovorin 20 vs 500/M2 | Jager 1996 | Abs | |||||
| Clinical Announcement 1991 | NCI | ||||||
| liver exclusive | ablation | links | |||||
| distant mets | Review | Coco 03 Onc SE CME 1:92 |
|||||
| D'Entremont 03 Onc SE 6:155 |
|||||||
| 5-FU+Leuc, qDx5 | Poon 1989 | Abs | fuleuc-dx5-met | ||||
| 5-FU+ Leuc, weekly | Jager 1996 | Abs | fuleuc-wk-met | ||||
| FU PVI | Hanson | Hansen-96 JNCI 88:668 |
|||||
| Irinotecan | Rothenberg | Rothenberg
99 Cancer 85:786 |
irino-6wk | ||||
| Irinotecan | Pitot 1997 | Abs | Pitot
97 jco 15:2910 |
irino-6wk | |||
| Irinotecan | Ulrich-Pur 2001 | Abs | Ulrich-Pur
01 Ann Oncol 12:1269 |
irino-3wk | |||
| FU+Leuc+Irino | Saltz | Abs | Saltz
00 NEJM 343:905 |
irino-fuleuc-irl-saltz | |||
| FOLFOX4 | Rothenberg | Abs | Rothenberg 2003 JCO 21:2059 |
folfox4 | |||
| Oxaliplatin toxicity mgmt | Pederiva 2004 | Abs | ASCO 04 abstract 282 |
folfox4, capox-4wk | |||
| Gamelin 2004 | Abs | Gamelin 04 Clin Ca Res 10:4055 |
folfox4, capox-4wk | ||||
| CapOx, dose-intense | Scheithauer 2003 | Abs | capox-4wk | ||||
| Capecitabine+Oxaliplatin | Twelves | Twelves
02 Onc 16 (12 Sup):22 |
|||||
| Avastin+5FU+Leuc (FLA) | Kabbinavar | Abs | Kabbinavar 03 JCO 21:60 |
fuleuc-wk-met avastin |
|||
| Avastin+Saltz (IFLA) | Genentech info | avastin | |||||
| Avastin+Saltz (IFLA) | Hurwitz | Abs | Hurwitz 04 NEJM 350:2335 |
irino-fuleu-ifl-saltz avastin |
|||
| Capecitabine+Irinotecan | Kim | Abs | Kim 05 Acta Onc 44:230 |
CapIri | |||
| Capecitabine+Irinotecan | Abs Abs | ||||||
| Capecitabine vs 5-FU | Cutsem | Cutsem 04 BJCa 90:1190 |
|||||
| Trifluridine+Tipiracil | Mayer | Mayer 15 |
|||||
Reviews: |
|||||||
| Rectal | |
||||||
| adjuvant | O'Connell 1994 | Abs | O'Connell
94 NEJM 331:502 |
rectal-adj | |||
| Clinical Announcement 1991 | NCI | ||||||
| neoadjuvant | capecitabine/leucovorin + RT | Kim | Kim 02 IJROBP 54(2):403 |
||||
| XELOX-RT | Rodel | Rodel 03 JCO 21:3098 |
|||||
| metastatic | see colon above | ||||||
| Anal | |
||||||
| definitive | Flam 1996 | Abs | Flam
96 JCO 14:2527 |
flam-anal | |||
| Kidney | |
||||||
| Sunitinib | |||||||
| Sorafenib | |||||||
| Pazopanib | |||||||
| Axitinib | Keating 2015 review | ||||||
| Everolimus | Motzer 2008 | ||||||
| Nivolumab vs everolimus | Motzer 2015 | ||||||
| Toxicity | Oliveira | ||||||
| Bladder | |
||||||
| MVAC | Loehrer | ||||||
| Gem+Cis | Kaufman 2000 | Abs | Kaufman
00 J Clin Oncol 18:1921 |
gem-cis-kaufman | |||
| Gem+Cis | Moore | Moore
99 JCO 17:2876 |
gem-cis-moore | ||||
| Gem+Cis vs MVAC | von der Maase | von
der Maase 00 JCO 17:3068 |
|||||
| Mito+5-FU with radiation | James | James 12 NEJM 366:1477 |
|||||
| Prostate | |
||||||
| localized | |||||||
| D1 | |||||||
| PSA Failure | definition | ASTRO 2003 | Web | CancerConsultants.com | |||
| D2 | hormonal | Samson | zoladex | ||||
| ASCO 2004 | Web | CancerConsultants.com | |||||
| Docetaxel+Prednisone | Eisenberger 2004 | Abs | Eisenberger 04 ASCO abstract No.4 |
doce-pred |
|||
| Mitoxantrone+Prednisone | Tannock 1996 | Abs | Tannock 96 JCO 4:1756 |
mitoxan-pred |
|||
| D3 | emcyt+VP | Pienta | Abs | Pienta
97 Urology 50:401 |
|||
| D3 | Zolendronic acid | ||||||
| Pamidronate | Small | Small
03 JCO 21:4277 |
|||||
| Prednisone role | Morgan | Morgan 14 Crit Rev Onc Chem 90:253 |
|||||
| Testicular | |
||||||
| PEB | Loehrer 1995 | Abs | Loehrer
95 JCO 13:470 |
peb | |||
| Breast | |
||||||
| adjuvant | |||||||
| locally adv. | |||||||
| metastatic | CMF | Harper-Wayne | |||||
| CAF | Stewart | ||||||
| Her2+Taxol | Slamon | ||||||
| Her2+Taxol | Seidman | ||||||
| male | |
||||||
| GYN | |||||||
| Ovarian | |
||||||
| Epithelial | |
||||||
| Germ Low MP |
|
||||||
| Endometrial | |
||||||
| Cervical | |
||||||
| Brain | |
||||||
|
|
glioma | PCV | MRC-BTWG | MRC-BTWP
01 JCO 19:509 |
|||
| correspondence re: above | Chamberlain | Chamberlain
01 JCO 19:3997 |
|||||
| PCV | Levin | Abs | Levin 80 Ca Treat Rep 64:237 |
pcv | |||
| oligodendro | PCV | Diabira | Diabira
01 JNeuro-Onc 55:45 |
||||
| TMZ | van den Bent | van
den Bent 01 Neuro 57:340 |
|||||
| Skin | |
||||||
| Melanoma, adjuvant | IFN alpha-2b, adjuvant | Kirkwood | Abs | Kirdwood
00 JCO 18:2444 |
|||
| Kirkwood | Abs | Kirkwood 01 JCO 19:2370 |
|||||
| Kirkwood | Abs | Kirkwood 04 Clin Ca Res 10:1670 |
|||||
| Sabel and Sondak | Abs | Sabel 03 The Oncologist 8:451 |
|||||
| Melanoma, node neg | IFN alpha-2b, IL2 adjuvant | Hauschild | |||||
| Melanoma, recurent | High Dose IL2 | Atkins | PPT | PowerPoint
presentation to National Academy of Sciences |
|||
| Vemurafenib | Chapman 2011 | ||||||
| Dabrafenib + trametinib | Robert 2015 Long 2014 |
||||||
| Sorafenib + cobimetinib | OncLive | ||||||
| Ipilumumab | |||||||
| Nivolumab + ipilumumab | Larkin 2015 | ||||||
| V600 mutations in non-melanoma | Hyman | Hyman 15 |
|||||
| Sarcoma | |
||||||
| Soft Tissue | Doxorubicin+Ifosfamide | Le Cesne 2000 | Abs | Le Cesne 00 JCO 18:2676 |
dox-ifos | ||
| MAID | Antman | Antman
98 Cancer 82:1288 |
|||||
| Osteosarcoma | |
||||||
| Unknown Primary | |||||||
| TFL (vs Cisplat+VP16) | Dowell | ||||||
| Other | |||||||
| Kaplan Meier | Rich 2010 | ||||||
The Heme-Onc Resouce page is continuously revised and updated.
Please send comments and suggestions to:
